Loading…
Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE
Pooled data from two large registries, Cubicin(®) Outcomes Registry and Experience (CORE; USA) and European Cubicin(®) Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients w...
Saved in:
| Published in: | Annals of clinical microbiology and antimicrobials 2016-03, Vol.15 (18), p.18-18, Article 18 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c560t-6030535aa09131462cb69312698d7f9e5b52c2bea13e008477c03414357832763 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c560t-6030535aa09131462cb69312698d7f9e5b52c2bea13e008477c03414357832763 |
| container_end_page | 18 |
| container_issue | 18 |
| container_start_page | 18 |
| container_title | Annals of clinical microbiology and antimicrobials |
| container_volume | 15 |
| creator | Seaton, R Andrew Gonzalez-Ruiz, Armando Cleveland, Kerry O Couch, Kimberly A Pathan, Rashidkhan Hamed, Kamal |
| description | Pooled data from two large registries, Cubicin(®) Outcomes Registry and Experience (CORE; USA) and European Cubicin(®) Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions.
Patients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Gram-positive infections were included. Clinical success was defined as an outcome of 'cured' or 'improved'. Post-treatment follow-up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infection; EU-CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infection). Safety was assessed for up to 30 days after daptomycin treatment.
In 11,557 patients (CORE, 5482; EU-CORE, 6075) treated with daptomycin (median age, 62 [range, 1-103] years), the most frequent underlying conditions were cardiovascular disease (54.7 %) and diabetes mellitus (28.0 %). The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 %) and bacteremia (21.8 %). The overall clinical success rate was 77.2 % (uncomplicated SSTI, 88.3 %; cSSTI, 81.0 %; osteomyelitis, 77.7 %; foreign body/prosthetic infection (FBPI), 75.9 %; endocarditis, 75.4 %; and bacteremia, 69.5 %). The clinical success rate was 79.1 % in patients with Staphylococcus aureus infections (MRSA, 78.1 %). An increasing trend of high-dose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to daptomycin therapy were reported in 628 (5.4 %) and 133 (1.2 %) patients, respectively.
The real-world data showed that daptomycin was effective and safe in the treatment of various Gram-positive infections, including those caused by resistant pathogens, across wide geographical regions. |
| doi_str_mv | 10.1186/s12941-016-0130-8 |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4791778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A446357655</galeid><sourcerecordid>A446357655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-6030535aa09131462cb69312698d7f9e5b52c2bea13e008477c03414357832763</originalsourceid><addsrcrecordid>eNptUk1r3DAQFaWhSbf9Ab0UQS-9OBlZtmT3UAjLpikEAqE5C608dhRky5XshP33lbNJmpQihEajN28-9Aj5xOCYsUqcRJbXBcuAibQ5ZNUbcsQKmW6Ssbcv7EPyPsZbgBxAyHfkMBe1FCyvjshwhdpl9z64hjZ6nHy_M3agc0SqTfAx0nvbIO3Qd0GPN9ZoRwN21g_xWzLi7KZI2-B7qunovcOG6kG7XbSR-pauL682ydHQzXW22B_IQatdxI-P54pcn21-rc-zi8sfP9enF5kpBUyZAA4lL7WGmnFWiNxsRc1ZKrtqZFtjuS1zk29RM44AVSGlAV6wgpey4rkUfEW-73nHedtjY3CYgnZqDLbXYae8tur1y2BvVOfvVCFrJhPJinx9JAj-94xxUr2NBp3TA_o5qgTiFVQg8gT98g_01s8hDWFB1bKCGmr-F9Vph8oOrU95zUKqTotCpMpFWSbU8X9QaTXYW-MHbG3yvwpg-4CHzwrYPvfIQC0iUXuRqCQStYhELb19fjmc54gnVfA_3oG0fw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1797809093</pqid></control><display><type>article</type><title>Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Seaton, R Andrew ; Gonzalez-Ruiz, Armando ; Cleveland, Kerry O ; Couch, Kimberly A ; Pathan, Rashidkhan ; Hamed, Kamal</creator><creatorcontrib>Seaton, R Andrew ; Gonzalez-Ruiz, Armando ; Cleveland, Kerry O ; Couch, Kimberly A ; Pathan, Rashidkhan ; Hamed, Kamal</creatorcontrib><description>Pooled data from two large registries, Cubicin(®) Outcomes Registry and Experience (CORE; USA) and European Cubicin(®) Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions.
Patients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Gram-positive infections were included. Clinical success was defined as an outcome of 'cured' or 'improved'. Post-treatment follow-up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infection; EU-CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infection). Safety was assessed for up to 30 days after daptomycin treatment.
In 11,557 patients (CORE, 5482; EU-CORE, 6075) treated with daptomycin (median age, 62 [range, 1-103] years), the most frequent underlying conditions were cardiovascular disease (54.7 %) and diabetes mellitus (28.0 %). The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 %) and bacteremia (21.8 %). The overall clinical success rate was 77.2 % (uncomplicated SSTI, 88.3 %; cSSTI, 81.0 %; osteomyelitis, 77.7 %; foreign body/prosthetic infection (FBPI), 75.9 %; endocarditis, 75.4 %; and bacteremia, 69.5 %). The clinical success rate was 79.1 % in patients with Staphylococcus aureus infections (MRSA, 78.1 %). An increasing trend of high-dose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to daptomycin therapy were reported in 628 (5.4 %) and 133 (1.2 %) patients, respectively.
The real-world data showed that daptomycin was effective and safe in the treatment of various Gram-positive infections, including those caused by resistant pathogens, across wide geographical regions.</description><identifier>ISSN: 1476-0711</identifier><identifier>EISSN: 1476-0711</identifier><identifier>DOI: 10.1186/s12941-016-0130-8</identifier><identifier>PMID: 26976128</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - therapeutic use ; Antimicrobial agents ; Asia ; Care and treatment ; Child ; Child, Preschool ; Complications and side effects ; Daptomycin - therapeutic use ; Europe ; Female ; Gram-Positive Bacteria - drug effects ; Gram-Positive Bacteria - physiology ; Gram-Positive Bacterial Infections - drug therapy ; Gram-Positive Bacterial Infections - microbiology ; Health aspects ; Humans ; Infant ; Infant, Newborn ; Latin America ; Male ; Microbiology ; Middle Aged ; Morbidity ; Registries ; Risk factors ; Staphylococcus aureus infections ; Treatment Outcome ; United States ; Young Adult</subject><ispartof>Annals of clinical microbiology and antimicrobials, 2016-03, Vol.15 (18), p.18-18, Article 18</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>Seaton et al. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-6030535aa09131462cb69312698d7f9e5b52c2bea13e008477c03414357832763</citedby><cites>FETCH-LOGICAL-c560t-6030535aa09131462cb69312698d7f9e5b52c2bea13e008477c03414357832763</cites><orcidid>0000-0003-1896-9736</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791778/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1797809093?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,25783,27957,27958,37047,37048,44625,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26976128$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seaton, R Andrew</creatorcontrib><creatorcontrib>Gonzalez-Ruiz, Armando</creatorcontrib><creatorcontrib>Cleveland, Kerry O</creatorcontrib><creatorcontrib>Couch, Kimberly A</creatorcontrib><creatorcontrib>Pathan, Rashidkhan</creatorcontrib><creatorcontrib>Hamed, Kamal</creatorcontrib><title>Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE</title><title>Annals of clinical microbiology and antimicrobials</title><addtitle>Ann Clin Microbiol Antimicrob</addtitle><description>Pooled data from two large registries, Cubicin(®) Outcomes Registry and Experience (CORE; USA) and European Cubicin(®) Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions.
Patients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Gram-positive infections were included. Clinical success was defined as an outcome of 'cured' or 'improved'. Post-treatment follow-up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infection; EU-CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infection). Safety was assessed for up to 30 days after daptomycin treatment.
In 11,557 patients (CORE, 5482; EU-CORE, 6075) treated with daptomycin (median age, 62 [range, 1-103] years), the most frequent underlying conditions were cardiovascular disease (54.7 %) and diabetes mellitus (28.0 %). The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 %) and bacteremia (21.8 %). The overall clinical success rate was 77.2 % (uncomplicated SSTI, 88.3 %; cSSTI, 81.0 %; osteomyelitis, 77.7 %; foreign body/prosthetic infection (FBPI), 75.9 %; endocarditis, 75.4 %; and bacteremia, 69.5 %). The clinical success rate was 79.1 % in patients with Staphylococcus aureus infections (MRSA, 78.1 %). An increasing trend of high-dose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to daptomycin therapy were reported in 628 (5.4 %) and 133 (1.2 %) patients, respectively.
The real-world data showed that daptomycin was effective and safe in the treatment of various Gram-positive infections, including those caused by resistant pathogens, across wide geographical regions.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antimicrobial agents</subject><subject>Asia</subject><subject>Care and treatment</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Complications and side effects</subject><subject>Daptomycin - therapeutic use</subject><subject>Europe</subject><subject>Female</subject><subject>Gram-Positive Bacteria - drug effects</subject><subject>Gram-Positive Bacteria - physiology</subject><subject>Gram-Positive Bacterial Infections - drug therapy</subject><subject>Gram-Positive Bacterial Infections - microbiology</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Latin America</subject><subject>Male</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Registries</subject><subject>Risk factors</subject><subject>Staphylococcus aureus infections</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>Young Adult</subject><issn>1476-0711</issn><issn>1476-0711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptUk1r3DAQFaWhSbf9Ab0UQS-9OBlZtmT3UAjLpikEAqE5C608dhRky5XshP33lbNJmpQihEajN28-9Aj5xOCYsUqcRJbXBcuAibQ5ZNUbcsQKmW6Ssbcv7EPyPsZbgBxAyHfkMBe1FCyvjshwhdpl9z64hjZ6nHy_M3agc0SqTfAx0nvbIO3Qd0GPN9ZoRwN21g_xWzLi7KZI2-B7qunovcOG6kG7XbSR-pauL682ydHQzXW22B_IQatdxI-P54pcn21-rc-zi8sfP9enF5kpBUyZAA4lL7WGmnFWiNxsRc1ZKrtqZFtjuS1zk29RM44AVSGlAV6wgpey4rkUfEW-73nHedtjY3CYgnZqDLbXYae8tur1y2BvVOfvVCFrJhPJinx9JAj-94xxUr2NBp3TA_o5qgTiFVQg8gT98g_01s8hDWFB1bKCGmr-F9Vph8oOrU95zUKqTotCpMpFWSbU8X9QaTXYW-MHbG3yvwpg-4CHzwrYPvfIQC0iUXuRqCQStYhELb19fjmc54gnVfA_3oG0fw</recordid><startdate>20160315</startdate><enddate>20160315</enddate><creator>Seaton, R Andrew</creator><creator>Gonzalez-Ruiz, Armando</creator><creator>Cleveland, Kerry O</creator><creator>Couch, Kimberly A</creator><creator>Pathan, Rashidkhan</creator><creator>Hamed, Kamal</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1896-9736</orcidid></search><sort><creationdate>20160315</creationdate><title>Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE</title><author>Seaton, R Andrew ; Gonzalez-Ruiz, Armando ; Cleveland, Kerry O ; Couch, Kimberly A ; Pathan, Rashidkhan ; Hamed, Kamal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-6030535aa09131462cb69312698d7f9e5b52c2bea13e008477c03414357832763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antimicrobial agents</topic><topic>Asia</topic><topic>Care and treatment</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Complications and side effects</topic><topic>Daptomycin - therapeutic use</topic><topic>Europe</topic><topic>Female</topic><topic>Gram-Positive Bacteria - drug effects</topic><topic>Gram-Positive Bacteria - physiology</topic><topic>Gram-Positive Bacterial Infections - drug therapy</topic><topic>Gram-Positive Bacterial Infections - microbiology</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Latin America</topic><topic>Male</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Registries</topic><topic>Risk factors</topic><topic>Staphylococcus aureus infections</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seaton, R Andrew</creatorcontrib><creatorcontrib>Gonzalez-Ruiz, Armando</creatorcontrib><creatorcontrib>Cleveland, Kerry O</creatorcontrib><creatorcontrib>Couch, Kimberly A</creatorcontrib><creatorcontrib>Pathan, Rashidkhan</creatorcontrib><creatorcontrib>Hamed, Kamal</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of clinical microbiology and antimicrobials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seaton, R Andrew</au><au>Gonzalez-Ruiz, Armando</au><au>Cleveland, Kerry O</au><au>Couch, Kimberly A</au><au>Pathan, Rashidkhan</au><au>Hamed, Kamal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE</atitle><jtitle>Annals of clinical microbiology and antimicrobials</jtitle><addtitle>Ann Clin Microbiol Antimicrob</addtitle><date>2016-03-15</date><risdate>2016</risdate><volume>15</volume><issue>18</issue><spage>18</spage><epage>18</epage><pages>18-18</pages><artnum>18</artnum><issn>1476-0711</issn><eissn>1476-0711</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>content type line 23</notes><abstract>Pooled data from two large registries, Cubicin(®) Outcomes Registry and Experience (CORE; USA) and European Cubicin(®) Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions.
Patients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Gram-positive infections were included. Clinical success was defined as an outcome of 'cured' or 'improved'. Post-treatment follow-up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infection; EU-CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infection). Safety was assessed for up to 30 days after daptomycin treatment.
In 11,557 patients (CORE, 5482; EU-CORE, 6075) treated with daptomycin (median age, 62 [range, 1-103] years), the most frequent underlying conditions were cardiovascular disease (54.7 %) and diabetes mellitus (28.0 %). The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 %) and bacteremia (21.8 %). The overall clinical success rate was 77.2 % (uncomplicated SSTI, 88.3 %; cSSTI, 81.0 %; osteomyelitis, 77.7 %; foreign body/prosthetic infection (FBPI), 75.9 %; endocarditis, 75.4 %; and bacteremia, 69.5 %). The clinical success rate was 79.1 % in patients with Staphylococcus aureus infections (MRSA, 78.1 %). An increasing trend of high-dose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to daptomycin therapy were reported in 628 (5.4 %) and 133 (1.2 %) patients, respectively.
The real-world data showed that daptomycin was effective and safe in the treatment of various Gram-positive infections, including those caused by resistant pathogens, across wide geographical regions.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>26976128</pmid><doi>10.1186/s12941-016-0130-8</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-1896-9736</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1476-0711 |
| ispartof | Annals of clinical microbiology and antimicrobials, 2016-03, Vol.15 (18), p.18-18, Article 18 |
| issn | 1476-0711 1476-0711 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4791778 |
| source | Open Access: PubMed Central; Publicly Available Content Database |
| subjects | Adolescent Adult Aged Aged, 80 and over Anti-Bacterial Agents - therapeutic use Antimicrobial agents Asia Care and treatment Child Child, Preschool Complications and side effects Daptomycin - therapeutic use Europe Female Gram-Positive Bacteria - drug effects Gram-Positive Bacteria - physiology Gram-Positive Bacterial Infections - drug therapy Gram-Positive Bacterial Infections - microbiology Health aspects Humans Infant Infant, Newborn Latin America Male Microbiology Middle Aged Morbidity Registries Risk factors Staphylococcus aureus infections Treatment Outcome United States Young Adult |
| title | Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T15%3A28%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-world%20daptomycin%20use%20across%20wide%20geographical%20regions:%20results%20from%20a%20pooled%20analysis%20of%20CORE%20and%20EU-CORE&rft.jtitle=Annals%20of%20clinical%20microbiology%20and%20antimicrobials&rft.au=Seaton,%20R%20Andrew&rft.date=2016-03-15&rft.volume=15&rft.issue=18&rft.spage=18&rft.epage=18&rft.pages=18-18&rft.artnum=18&rft.issn=1476-0711&rft.eissn=1476-0711&rft_id=info:doi/10.1186/s12941-016-0130-8&rft_dat=%3Cgale_pubme%3EA446357655%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c560t-6030535aa09131462cb69312698d7f9e5b52c2bea13e008477c03414357832763%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1797809093&rft_id=info:pmid/26976128&rft_galeid=A446357655&rfr_iscdi=true |